Principles behind SLE treatment with N -acetylcysteine.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing molecular mechanisms, preclinical studies, and previously published trial data without new empirical data
PubMed 36312742 · doi:10.1097/IN9.0000000000000010
What was done
This narrative review summarizes the molecular mechanisms, preclinical evidence, and preliminary trial findings regarding N-acetylcysteine (NAC) as an antioxidant therapy for systemic lupus erythematosus (SLE).
What was found
The abstract provides a qualitative summary of mechanisms and previously reported findings without providing quantitative data. Reported mechanisms include mitochondrial hyperpolarization, ATP and glutathione depletion, diminished mitophagy, and kynurenine accumulation in SLE. The abstract notes that kynurenine accumulation was reversed by NAC compared to placebo in a referenced 3-month double-blind clinical trial, but no numerical values, effect sizes, or participant numbers are stated.
Why it matters
NAC may target underlying mitochondrial oxidative stress and glutathione depletion in SLE, representing a potentially well-tolerated adjunctive therapeutic approach.
Limits
As a narrative review, no new empirical human data are presented. The abstract omits sample sizes, quantitative effect estimates, and statistical measures for the referenced clinical trial, and several findings derive from lupus-prone mouse models.
Cited by
- supports Supplementation with N-acetylcysteine (NAC) enhances glutathione production.